CARsgen receives IND clearance for cell therapy

By The Science Advisory Board staff writers

May 18, 2020 -- CARsgen Therapeutics has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a cell therapy drug for advanced gastric and pancreatic cancer.

The drug, called CT041 humanized anti-claudin18.2 autologous chimeric antigen receptor (CAR) T cells (CT041), is the first of its kind cleared for clinical trials in the world, CARsgen said. The IND clearance was supported by a phase I trial conducted at Beijing Cancer Hospital at Peking University in China. A phase 1b trial will begin in the third quarter of this year, according to the firm.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.